BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 1557647)

  • 1. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Lenk H; Wiener N; Boese-Landgraf J; Schalhorn A
    Semin Oncol; 1992 Apr; 19(2 Suppl 4):57-62. PubMed ID: 1553576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
    Schmoll HJ; Köhne-Wömpner CH; Hiddemann W; Knipp H; Wilke H; Bodenstein H; Schöffski P; Bokemeyer C; Lohrmann HP; Preiss J
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):191-6. PubMed ID: 1557646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer.
    Preiss J
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):220-4. PubMed ID: 1557652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
    Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
    Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.
    Köhne CH; Wilke H; Hiddemann W; Bokemeyer C; Lohrmann HP; Bodenstein H; Preiss J; Rauschecker H; Hill H; Kaufer C; Fischer JT; Ohl U; Urbanitz D; Balleisen L; Schmoll HJ
    Oncology; 1997; 54(2):96-101. PubMed ID: 9075778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. First results of a randomized multicenter study by the Association of Medical Oncology of the German Cancer Society (AIO).
    Köhne CH; Wilke H; Hecker H; Schöffski P; Käufer C; Rauschecker H; Andreesen R; Ohl U; Lange HJ; Klaassen U
    Ann Oncol; 1995 May; 6(5):461-6. PubMed ID: 7669711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.
    Patt YZ; Hoque A; Lozano R; Pozdur R; Chase J; Carrasco H; Chuang V; Delpassand ES; Ellis L; Curley S; Roh M; Jones DV
    J Clin Oncol; 1997 Apr; 15(4):1432-8. PubMed ID: 9193336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
    Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
    Kerr DJ; Ledermann JA; McArdle CS; Buckels J; Neoptolemos J; Seymour M; Doughty J; Budden J; Taylor I
    J Clin Oncol; 1995 Dec; 13(12):2968-72. PubMed ID: 8523062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
    J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective biomodulation by leucovorin of high-dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer.
    Köhne CH; Schöffski P; Wilke H; Käufer C; Andreesen R; Ohl U; Klaasen U; Westerhausen M; Hiddemann W; Schott G; Harstick A; Bade J; Horster A; Schubert U; Hecker H; Dörken B; Schmoll HJ
    J Clin Oncol; 1998 Feb; 16(2):418-26. PubMed ID: 9469324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of 5-fluorouracil, leucovorin and interferon-alpha 2b administered by 24 h infusion in metastatic colorectal carcinoma.
    Cascinu S; Del Ferro E; Ligi M; Catalano G
    Anticancer Drugs; 1996 Jul; 7(5):520-4. PubMed ID: 8862717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study with paclitaxel in combination with weekly high-dose 5-fluorouracil/folinic acid in the treatment of metastatic breast cancer: an interim analysis.
    Klaassen U; Wilke H; Pari CP; Strumberg D; Harstrick A; Eberhardt W; Becher R; Diergarten K; Seeber S
    Semin Oncol; 1995 Dec; 22(6 Suppl 14):7-11. PubMed ID: 8553083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
    Vokes EE; Ratain MJ; Mick R; McEvilly JM; Haraf D; Kozloff M; Hamasaki V; Weichselbaum RR; Panje WR; Wenig B
    J Clin Oncol; 1993 Feb; 11(2):360-8. PubMed ID: 8426214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
    Punt CJ; Burghouts JT; Croles JJ; van Liessum PA; de Mulder PH; Kamm Y
    Cancer; 1993 Oct; 72(7):2107-11. PubMed ID: 8374869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatic arterial infusion (HAI). Comparison of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres versus 5-fluorouracil and folinic acid in patients with non-resectable colorectal liver metastases.
    Pohlen U; Rieger H; Mansmann U; Berger G; Buhr HJ
    Anticancer Res; 2006; 26(5B):3957-64. PubMed ID: 17094427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
    Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
    J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorouracil continuous infusion plus alfa interferon plus oral folinic acid in advanced colorectal cancer.
    Punt CJ; de Mulder PH; Burghouts JT; Wagener DJ
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):208-10. PubMed ID: 1557649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.